Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins)

Read full text Summarise with VIRAT
Authors: Danièle Dubois‐Laforgue, Bruno Donadille, Cécile Ciangura, Chloé Amouyal, Jean‐Baptiste Arnoux, Pascal Barat, Sabine Baron, Jacques Beltrand, Élise Bismuth, C. Bouché, Jean‐Claude Carel, Hélène Cavé
+23 more Sophie Christin‐Maître, Delphine Collin‐Chavagnac, Christiane Damgé, Brigitte Delemer, Pierre Gourdy, Sophie Jacqueminet, Sonja Janmaat, Marc De Kerdanet, Laurence Kessler, Dominique Langin, Jean‐Charles Nault, J. Nizard, Michel Polak, Rachel Reynaud, Cécile Saint‐Martin, Igor Tauveron, René Valéro, A. Vambergue, Marie‐Christine Vantyghem, Camille Vatier, Marc P Nicolino, Christine Bellanné‐Chantelot, Corinne Vigouroux
Cited by: 0
References: 69

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

MODY (Maturity-Onset Diabetes of the Young) is characterized by autosomal dominant mode of inheritance, early onset of diabetes in the absence of autoimmunity directed to pancreatic β-cells, impaired insulin secretory capacity, however, maintained over time, and extra-pancreatic manifestations in some patients. Its prevalence has been estimated 0.6% to 6.5% of all diabetes in Europe and the USA. Pathogenic variants in the genes encoding glucokinase or transcription factors HNF1A or HNF4A are responsible for the majority of cases of monogenic forms of diabetes referred to as MODY. The objective of the French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins) dedicated to GCK-MODY (formerly MODY2), HNF1A-MODY (MODY3), and HNF4A-MODY (MODY1) is to provide to health professionals a guide for optimal management and care of patients, based on a critical literature review and multidisciplinary expert consensus. The PNDS, written by members of the French National Reference Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), is available on the French Health Authority website (in French). Thorough analysis of personal and family history, clinical examination and biochemical testing are key to raise the diagnosis, which has to be confirmed by molecular analysis. The attending physician, in conjunction with the national care network, will ensure that the patient receives optimal care through regular follow-up and screening. Overall, the management of patients with MODY requires the collaboration of several health care providers.

Fields of Study & Subjects

Pancreatic function and diabetes Diabetes and associated disorders Genomics and Rare Diseases

Publication details

Journal / source
Orphanet Journal of Rare Diseases
Volume
17
Issue
S1
Pages
452
Publication date
31 March 2026
Language
EN